These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3124166)

  • 21. Clinical perspectives of some neuroleptics through development and application of their assays.
    Midha KK; Marder SR; Jaworski TJ; McKay G; Hubbard JW; Hawes EM; Van Putten T; Wirshing WC; Aravagiri M
    Ther Drug Monit; 1993 Jun; 15(3):179-89. PubMed ID: 8101398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
    Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
    Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters.
    Viala A; Hou N; Ba B; Durand A; Dufour H; D'Agostino N; Berda C; Jørgensen A
    Psychopharmacology (Berl); 1984; 83(2):147-50. PubMed ID: 6146995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluphenazine plasma levels and clinical response.
    Marder SR; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J; Midha KK
    Psychopharmacol Bull; 1990; 26(2):256-9. PubMed ID: 2236467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
    Wistedt B
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioimmunoassay for fluphenazine sulfoxide in human plasma.
    Midha KK; Hawes EM; Hubbard JW; McKay G; Rauw G; Sardessai MS; Aravagiri M; Moore MD
    J Pharmacol Methods; 1988 Mar; 19(1):63-74. PubMed ID: 3367650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
    Altamura AC; Mauri MC; Girardi T; Panetta B
    Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma levels of fluphenazine decanoate. Effects of site of injection, massage and muscle activity.
    Soni SD; Wiles D; Schiff AA; Bamrah JS
    Br J Psychiatry; 1988 Sep; 153():382-4. PubMed ID: 3250675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitive method for the simultaneous measurement of fluphenazine decanoate and fluphenazine in plasma by high-performance liquid chromatography with coulometric detection.
    Luo JP; Hubbard JW; Midha KK
    J Chromatogr B Biomed Sci Appl; 1997 Jan; 688(2):303-8. PubMed ID: 9061468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluphenazine decanoate dose and severity of depression in patients with post-psychotic depression.
    Siris SG; Strahan A; Mandeli J; Cooper TB; Casey E
    Schizophr Res; 1988; 1(1):31-5. PubMed ID: 3154504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G; Coyle J; Tune L
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients.
    Van Putten T; Aravagiri M; Marder SR; Wirshing WC; Mintz J; Chabert N
    Psychopharmacol Bull; 1991; 27(2):91-6. PubMed ID: 1924666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low neuroleptic serum levels in patients receiving fluphenazine decanoate.
    Tune LE; Creese I; Coyle JT; Pearlson G; Snyder SH
    Am J Psychiatry; 1980 Jan; 137(1):80-2. PubMed ID: 6101523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate.
    Viala A; Ba B; Durand A; Gouezo F; Hou N; Jørgensen A
    Psychopharmacology (Berl); 1988; 94(3):293-7. PubMed ID: 2895936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.
    Altamura AC; Curry SH; Montgomery S; Wiles DH
    Psychopharmacology (Berl); 1985; 87(1):30-3. PubMed ID: 3933035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man.
    Curry SH; Whelpton R; de Schepper PJ; Vranckx S; Schiff AA
    Br J Clin Pharmacol; 1979 Apr; 7(4):325-31. PubMed ID: 444352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroleptic serum levels measured by radioreceptor assay in patients receiving intramuscular depot neuroleptics. Some preliminary findings.
    Turbott J; Villiger J; Hunter L
    Br J Psychiatry; 1985 Apr; 146():439-42. PubMed ID: 4016448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depot fluphenazine decanoate and enanthate for schizophrenia.
    David A; Adams CE; Eisenbruch M; Quraishi S; Rathbone J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD000307. PubMed ID: 15674872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
    Cookson JC; Kennedy NM; Gribbon D
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.